Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Unusually-High Trading Volume – What’s Next?

Posted by Hanz Christensen on Jul 9th, 2026

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) shares saw unusually-strong trading volume on Thursday . 302,556 shares changed hands during trading, an increase of 126% from the previous session’s volume of 134,092 shares.The stock last traded at $12.1050 and had previously closed at $12.20.

Wall Street Analyst Weigh In

Separately, Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, June 23rd. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy”.

Check Out Our Latest Stock Report on Fresenius SE & Co.

Fresenius SE & Co. Price Performance

The company has a 50 day moving average of $11.42 and a 200 day moving average of $13.04. The stock has a market capitalization of $27.33 billion, a price-to-earnings ratio of 16.17 and a beta of 0.63. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 0.41.

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Fresenius SE & Co. had a net margin of 6.55% and a return on equity of 10.09%. The business had revenue of $6.75 billion during the quarter, compared to analysts’ expectations of $6.79 billion. As a group, equities research analysts forecast that Fresenius SE & Co. will post 1.03 EPS for the current fiscal year.

About Fresenius SE & Co.

(Get Free Report)

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.